Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.46 |
| ▸ | BRAF | P15056 | 4/20 | 0.43 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | SNCA | P37840 | 1/20 | 0.42 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.41 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL299098 | 0.86 | CYP3A4 (0.51) | CYP3A4CYP2C19PIK3CACYP2C9BRAF | |
| SCHEMBL298357 | 0.85 | CYP3A4 (0.52) | CYP3A4CYP2C19PIK3CACYP2C9SLC40A1 | |
| SCHEMBL297762 | 0.85 | PIK3CA (0.54) | CYP3A4CYP2C19PIK3CACYP2C9BRAF | |
| SCHEMBL299292 | 0.84 | CYP3A4 (0.50) | CYP3A4CYP2C19PIK3CACYP2C9BRAF | |
| SCHEMBL293639 | 0.84 | CYP3A4 (0.80) | CYP3A4CYP2C19CYP2C9BRAFMAP2K4 | |
| SCHEMBL298860 | 0.80 | CYP3A4 (0.54) | CYP3A4CYP2C19CYP2C9BRAFKMT2A | |
| SCHEMBL298074 | 0.79 | CLK1 (0.46) | CYP3A4CYP2C9BRAFKMT2A | |
| SCHEMBL409620 | 0.79 | CYP2C9 (0.54) | CYP3A4CYP2C19PIK3CACYP2C9BRAF | |
| SCHEMBL858685 | 0.79 | CYP3A4 (0.59) | CYP3A4CYP2C19PIK3CACYP2C9BRAF | |
| SCHEMBL298354 | 0.79 | CYP3A4 (0.53) | CYP3A4CYP2C19PIK3CACYP2C9BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. | 2012-05-17 | — | — | US | disclosed |
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. | 2012-05-17 | — | — | US | disclosed |
| EP-2427433-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | Plexxikon, Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010129570-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | BRAF, RAF1, ARAF | CYP3A4 3611/4885CYP2C19 2730/4885PIK3CA 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.